THLD took a massive hit today, and has flatlined around 3.30. Im thinking about jumping in for a possible rally on monday. what do you guys think?
i bought 4000 this morning at 3.16 sold 1000 for 3.33 i wonder how much its shorted maybe there will some short covering the next day the nasdaq goes green
possible chance to catch a quick run up next week. the stocks reaction to the fda stopping of their trials is an over reaction i think, shouldnt have dropped down this low, and will recover some next week. im going to take advantage of it.
did you see the downgrades lol big deal one year target is stil 14
12-May-06 CIBC Wrld Mkts Downgrade Sector Outperform to Sector Perform
12-May-06 Morgan Stanley Downgrade Overweight to Equal-weight
12-May-06 Cowen & Co Downgrade Outperform to Neutral
12-May-06 Lazard Captial Downgrade Buy to Hold
Quote from: shriep on May 12, 2006, 02:30:49 PM
possible chance to catch a quick run up next week. the stocks reaction to the fda stopping of their trials is an over reaction i think, shouldnt have dropped down this low, and will recover some next week. im going to take advantage of it.
they didnt stop the trials
partially suspended
UPDATE 1-Threshold says FDA partially suspends drug trial
LOS ANGELES, May 11 (Reuters) - Threshold Pharmaceuticals Inc.(THLD.O: Quote, Profile, Research) said on Thursday the U.S. Food and Drug Administration partially suspended a late stage clinical trial of a drug for enlarged prostate after six participants showed liver problems, sending its shares down 76.1 percent in after hours trading.
The problems included "adverse events" in three men in the phase 3 European/Canadian clinical trial, and three others who had elevated liver enzymes in other trials, Threshold said in a statement.
The drug, TH-070, or lonidamine, was first approved to treat cancer in three European countries in the mid-1980s.
The company said the FDA has requested additional information related to the drug's acceptable dose and duration of treatment in patients with benign prostatic hyperplasia.
The company said it would stop administering the drug to 567 patients enrolled in phase 3 of its European and Canadian trial.
Threshold said it would continue two other trials but was withdrawing another trial that had been planned for this year.
"Our main priority right now is the safety of our patients and we are working with the FDA to resolve these safety issues as quickly as possible," said Alan Colowick, Threshold's chief medical officer.
Be careful on these big gap downs. From my experience these biotech gap down stocks is that it takes 3 to 6 months to enter that gap. Believe me it will test that 3.52 level a couple of times before it breaks and holds above that level. ENCY, NABI, ELN are some expamples. One to keep an eye on but not for awhile.
I think eventually, it will partially fill that gap. Will be watching Monday.
THLD to be added to the biotech index,
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B89AA49CD%2D7149%2D413D%2D922B%2D5EB01A502C33%7D&siteid=mktw&sid=1927606&symb=
any body in this besides me? i bought alot more on yesterdays selloff. im no chart person but since yestrdays sell off it looks like it is making higher lows and higher highs on the 1 day chart.do you think its redy to turn around now? most are saying that it oversold on the news.
THRESHOLD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
http://biz.yahoo.com/e/060515/thld10-q.html
Quote from: stocks2watch2 on May 15, 2006, 09:00:21 AM
THLD to be added to the biotech index,
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B89AA49CD%2D7149%2D413D%2D922B%2D5EB01A502C33%7D&siteid=mktw&sid=1927606&symb=
Keep an eye on THLD, it will be added to the index on Monday.
Bought 16,000 @ 3.25.
Breaking out to hod.
3.40 ;D
Looks like the shorts are covering ;D Should see a gap up Monday.
Price 3.70
Strong close @ the hod 3.79. Sold 6000 @ 3.75.
Looking good, over 1 mill. shares traded.
Up .53 @ 4.32 ;D
Nice breakout, sold 2000 @ 4.45 on this run. Anyone still in? We may go to 5.00 tom?
i think i sold to soon :( i hope you get you 5 dollars its 4.75 in pre market trading
REDWOOD CITY, Calif., June 1, 2006 /PRNewswire-FirstCall via COMTEX/ -- Threshold Pharmaceuticals, Inc. (THLD, Trade), today announced that the Independent Data Monitoring Committee (IDMC) recently evaluated the data collected to date from the Company's ongoing pivotal phase 3 clinical trial of glufosfamide for the second-line treatment of patients with metastatic pancreatic cancer. The IDMC concluded that the trial can continue to completion.
For the planned interim analysis the IDMC could have recommended stopping the trial early if there were major safety concerns in the glufosfamide arm. After reviewing the interim data the IDMC recommended to continue the study to completion.
"This is an important milestone in the development of this novel therapy," said Alan Colowick, M.D., chief medical officer at Threshold. "We anticipate announcing top-line results at the end of the fourth quarter this year. We are hopeful that, if successful in this trial, glufosfamide will give patients another treatment option against this deadly cancer."
Broke into Gap above 1.87. $3 next level to close the gap :o
THLD went into the gap this morning, buyout rumored. What'cha think? tgt $3
In THLD yesterday @ 2.05 ;D
Tight stop
Looking good-into the gap ;D
More volume and we may take off!
hi,
got filled at 208 today,
, looks good ,
maxi
It does look good Maxi, good luck to us!
I wouldn't be surprised to see it gap in the morning. Plenty of volume and a close at HOD is bullish for sure! ;D
hi,
sold at 230.
could see it pulling back for the day. may get in at support. we'll see.
maxi
Stopped out even ::)
nice daY THLD!
maxi
THLD gapped up and is holding up to near daily highs on strong volume. No black candle for THLD which is always a good sign ;)
Institutional buying happening !!!!!!! ;D :o
Nice Close. Next target $4.75 then $14 :o
AP
Threshold Pharma Up on Positive Trial
Thursday December 28, 4:58 pm ET
Threshold Pharmaceuticals Up on Positive Cancer-Drug Trial Data
NEW YORK (AP) -- Shares of Threshold Pharmaceuticals Inc. leaped Thursday after the biotechnology company reported good mid-stage trial results for its drug against advanced pancreatic cancer, used with the chemotherapy drug gemcitabine.
Stock of the Redwood City, Calif.-based company jumped 91 cents, or 28.44 percent, to close at $4.11 on the Nasdaq Stock Market.
Thursday's strongest level, on heavy volume, was $4.23. On a 52-week basis, there was a high of $16.98 on April 17 and a low of $1.42 on July 24.
Threshold said that out of 28 cancer patients taking its drug, glufosfamide, 21 percent showed about a 30 percent decease in lesion size, while the progression of lesions in 36 percent of patients ceased.
For comparison, late-stage trial data for just gemcitabine-brand name Gemzar demonstrated a 5 percent response rate, according to Lazard Capital Markets analyst Joel Sendek.
Even though Threshold's glufosfamide data are encouraging, the drug nonetheless faces strong competition from OSI Pharmaceuticals Inc.'s Tarceva, and potentially from Genentech Inc.'s Avastin and Imclone Systems Inc.'s Erbitux.
"We model glufosfamide 2008-2010 U.S. sales of $11.7 million, $21.9 million, and $45.6 million, respectively," Sendek said in a research note.
Threshold doesn't have any drugs on the market. In 2005, the company posted a loss of $44.4 million, or $1.63 a share, on revenue of $690,000.
On May 12, Threshold shares dropped as much as 80 percent to $3 after the drug developer revealed the U.S. Food and Drug Administration had halted clinical trials of the company's lead drug candidate, TH-070, because of liver toxicity. That drug was for treatment of benign prostatic hyperplasia and aimed at providing rapid symptom improvement by targeting overgrown prostate cells.
The company later dropped development of the drug altogether.
On Thursday, Threshold said glufosfamide was generally well tolerated in combination with gemcitabine, but that the incidence of treatment-related toxicity to the kidneys "may be slightly higher" than in earlier observations of the drugs used individually.
Lazard Capital has had an investment-banking relationship with the company but Sendek doesn't own any shares.
(THLD).......
RECEIVES NASDAQ NON-COMPLIANCE NOTICE: Threshold Pharmaceuticals, Inc. (THLD)
received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating
that the Company does not comply with the $1.00 minimum bid price requirement for continued
listing. Threshold will have 180 days, or until April 16, 2008, to regain compliance.
Up big today...dont own.
http://biz.yahoo.com/pz/080118/134580.html (http://biz.yahoo.com/pz/080118/134580.html)